NAD+ Infusions

NAD+ infusions have garnered attention in the field of longevity and anti-aging medicine. These intravenous treatments aim to increase the levels of Nicotinamide Adenine Dinucleotide (NAD+) within the body. NAD+ is a crucial compound involved in various physiological processes, including metabolism, energy production, DNA repair, and cell aging.

NAD+ infusions involve delivering a high concentration of NAD+ directly into the bloodstream. This process bypasses the digestive system, allowing for increased bioavailability and immediate uptake by the cells. The procedure typically takes a couple of hours and is administered by healthcare professionals in a clinical setting. The concentrations of NAD+ used in infusions can vary, but they typically range from 100 mg to 1000 mg per infusion. The actual concentration administered would depend on the individual's health condition, body weight, and the specific clinical protocol or physician's recommendation.

The dose and frequency of NAD+ infusions are typically tailored to the individual, based on their health goals or medical needs, and a healthcare provider's assessment. It’s crucial for individuals considering NAD+ infusion therapy to discuss the appropriate dose and frequency with a qualified healthcare professional or a physician experienced in administering NAD+ infusions to ensure safety and efficacy. Keep in mind that more research is needed to establish optimal dosing protocols and to fully understand the long-term effects and efficacy of NAD+ infusions.

NAD+ infusions can indeed temporarily increase NAD+ levels in the body, but the duration of the increase varies and is influenced by individual metabolic rates, lifestyle, and overall health. It can last from a few hours to a few days. Typically, within a few days, the levels start to normalize as NAD+ is consumed in metabolic processes or excreted.

Potential Benefits

NAD+ infusions have been suggested to offer several potential benefits, related to the enhancement of cellular functions and mitigation of aging-related decline:

Improved Energy Levels: By optimizing cellular energy production, NAD+ infusions can lead to increased vitality and reduced fatigue.
Enhanced Brain Function: NAD+ is essential for neuronal health and function, and infusions can potentially improve cognitive function, focus, and memory.
Cellular Repair and Maintenance: Elevated NAD+ levels aid in DNA repair and maintenance of cell integrity, potentially reducing aging-related cellular damage and dysfunction.
Longevity: By mitigating age-related decline in cellular function, NAD+ infusions may have implications in promoting longevity and reducing the risk of age-related diseases.

Risks and Considerations

While NAD+ infusions are generally considered safe, some individuals may experience side effects, including nausea, flushing, and light-headedness. The long-term effects and optimal dosing of NAD+ infusions remain subjects of ongoing research. Prospective recipients should consider the current state of scientific knowledge and consult healthcare providers for personalized advice and assessment of individual health conditions.

Research and Evidence

The efficacy and safety of NAD+ infusions are still under investigation, with some preliminary studies indicating potential benefits in terms of cellular energy enhancement and anti-aging effects. However, more extensive and rigorous clinical trials are needed to substantiate these claims and establish therapeutic protocols.

Comparison with NMN/NR Supplementation

	NAD+ Infusions	NMN / NR
Administration	Direct intravenous infusion	Oral (Supplement)
Bioavailability and Efficacy	High; Immediate and pronounced effects	Good; Gradual increase in NAD+ levels
Duration of Effect	Varies; Immediate effects	Sustained; Requires regular supplementation
Cost and Accessibility	Expensive; Clinical settings	Affordable; Over-the-counter
Safety and Side Effects	Safe when administered professionally; Potential side effects include nausea and chest tightness	Generally well tolerated; Minimal side effects at recommended doses

Todo

2019, A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD ^[1]

References

↑ Grant R et al.: A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci 2019. (PMID 31572171) [PubMed] [DOI] [Full text] Accumulating evidence suggests that active maintenance of optimal levels of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is beneficial in conditions of either increased NAD+ turnover or inadequate synthesis, including Alzheimer's disease and other neurodegenerative disorders and the aging process. While studies have documented the efficacy of some NAD+ precursors such as nicotinamide riboside (NR) in raising plasma NAD+, no data are currently available on the fate of directly infused NAD+ in a human cohort. This study, therefore, documented changes in plasma and urine levels of NAD+ and its metabolites during and after a 6 h 3 μmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR) and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant rise in urinary nicotinamide was observed. This study revealed for the first time that: (i) at an infusion rate of 3 μmol/min NAD+ is rapidly and completely removed from the plasma for at least the first 2 h; (ii) the profile of metabolites is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products arising from an NAD+ infusion include NAD+ itself and methyl nicotinamide (meNAM) but not NAM.

[pmid31572171-1] Grant R et al.: A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci 2019. (PMID 31572171) [PubMed] [DOI] [Full text] Accumulating evidence suggests that active maintenance of optimal levels of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is beneficial in conditions of either increased NAD+ turnover or inadequate synthesis, including Alzheimer's disease and other neurodegenerative disorders and the aging process. While studies have documented the efficacy of some NAD+ precursors such as nicotinamide riboside (NR) in raising plasma NAD+, no data are currently available on the fate of directly infused NAD+ in a human cohort. This study, therefore, documented changes in plasma and urine levels of NAD+ and its metabolites during and after a 6 h 3 μmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR) and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant rise in urinary nicotinamide was observed. This study revealed for the first time that: (i) at an infusion rate of 3 μmol/min NAD+ is rapidly and completely removed from the plasma for at least the first 2 h; (ii) the profile of metabolites is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products arising from an NAD+ infusion include NAD+ itself and methyl nicotinamide (meNAM) but not NAM.

[1]